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Abstract
Background: the fecal pancreatic elastase-1 (EL-1) test is a new non-invasive test for pancreatic function. The aim of the study
was to evaluate the intra-patient variability of the fecal EL-1 test in a cystic fibrosis (CF) population. Methods: 26 CF patients
were recruited. Mean patient (S.D.) age was 13.7 years (5.39). Nineteen patients had classical pancreatic insufficiency (PI) based
on a clinical syndrome of malabsorption plus steatorrhea on a 72 h fecal fat balance. They were all treated with enzyme
supplements. Four patients had classical pancreatic sufficiency (PS): no symptoms of malabsorption, no steatorrhea on a 72 h
fecal fat balance, no enzyme treatment. Two patients had symptoms suggestive of PI but had a normal 72 h fecal fat balance:
(doubtful pancreatic status (PD)). The CF patients were asked to collect stool samples on 7 consecutive days. EL-1 content in
the samples was measured in duplicate. A cut-off of 200 mgEL-1yg stool was used for diagnosing PI. Results: mean intra-assay
variability was 4.06%. All PI patients had EL-1 levels below detection limit. For the PS group maximal intra-patient variability
was 35%, one stool sample EL-1 level was below the 200-mg cut-off. In the PD group the maximal intra-patient variability was
37% and EL-1 levels were inconclusive for the diagnosis of PI in both patients. Conclusions: the EL-1 test can be used for
diagnosing severe PI in CF patients with overt clinical symptoms of malabsorption. However, in CF patients where the clinical
picture is less clear the EL-1 test may be inconclusive due to significant intra-patient variability.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cystic fibrosis (CF) is the single most common cause
of exocrine pancreatic insufficiency (PI) in childhood.
Eighty five percent of CF patients have PI and need
pancreatic enzyme replacement therapy. The diagnosis
of PI is suspected on clinical grounds. The most frequent
symptoms include neonatal meconium ileus, steatorrhea
with frequent offensive and bulky stools and failure to
thrive w1x.
Epidemiologic surveys have indicated that CF patients
who have pancreatic sufficiency (PS) have a milder
disease course than those who have PI w2,3x.
Surprisingly, no simple reliable method is available
to determine pancreatic function. Intubation of the duo-
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denum and collection of pancreatic secretions for anal-
ysis of pH and enzymes after stimulation by secretin
and cholecystokinin-pancreozymin is the gold standard.
However, the procedure is invasive, expensive and labor-
intensive which makes it less useful in daily practice
w4x. A number of non-invasive tests have therefore been
developed. The 72-h fecal fat analysis is most frequently
used. Fat malabsorption is diagnosed when fecal fat loss
exceeds 7% of the amount of dietary fat. The test has
its drawbacks in that the dietary history may not be
reliable and that the stool collection may be incomplete
w5x.
Pancreatic elastase-1 (EL-1) is a protease secreted by
the acinar cells of the pancreas and is highly stable
during intestinal transit. EL-1 is stable in feces at room
temperature during 1 week, at 4 8C during 1 month and
aty22 8C for longer time w6x. Because, EL-1 is species-
specific it can be differentiated from the porcine elastase
present in enzyme supplements. Using a cut-off of 200
mgEL-1yg stool Cade et al. found a specificity of 86%














Patients are grouped according to pancreatic function: 19 patients
had classical PI, 4 had classical PS and 2 had PD.
and a sensitivity of 99% to diagnose PI in a pediatric
CF population w7x. A sandwich-ELISA kit is commer-
cially available (Schebo. Tech, Giessen, Germany).
Intra-patient variability has been studied in normal
subjects and was low (range 9–28%) w6,8x. However,
intra-patient variability has hardly been studied in CF
patients. Our concern about this lack of information was
raised after one of our CF patients with unclear pancre-
atic status on clinical grounds and on fecal fat analysis
had fecal EL-1 quantification performed on three occa-
sions, with test results ranging from below the cut-off
to values suggesting PS.
The aim of this study was therefore to evaluate the
intra-patient variability of EL-1 in stool samples of CF
patients.
2. Patients and methods
2.1. Patients
Twenty five CF patients (14 male, 11 female) were
recruited from the CF clinic at the University Hospital
Gasthuisberg. The age range was 2.2–22 years with
mean (S.D.) patient age 13.6 (5.54) years. CF was
diagnosed according to international guidelines based
on clinical criteria, pilocarpine iontophoresis sweat test-
ing on two occasions andyor CFTR mutation analysis
w1x. In all patients 72 h fecal fat analysis was performed
according to the method of Van de Kamer et al. w9x.
Nineteen patients had classical PI, defined as the occur-
rence of bulky stools andyor failure to thrive and a fecal
fat loss exceeding 7% of fat intake as determined by a
72 h fecal fat analysis. Four patients had classical PS,
defined as absence of both bulky stools and failure to
thrive, and a fecal fat loss below 7% upon 72 h fecal
fat balance. In 2 patients bulky stools andyor failure to
thrive were present, however, fecal fat loss was below
7% upon repeated testing. These patients are further
denoted as having a doubtful pancreatic status (PD).
Patient genotyping is represented in Table 1.
All patients were asked to collect stool samples on 7
consecutive days. In the PI group, 16 patients collected
7 samples, 2 collected 5 and 1 only 3. In the PS group,
2 collected 7 samples, 1 sent 5 samples and 1 patient
only 2. Two patients with PD collected 7 samples.
Stool samples were stored at 4 8C before they reached
the hospital. They were sent by mail or brought to the
clinic. Each stool sample was halved and one half was
sent to the Schebo quality control lab for analysis as a
control to our method. Storage prior to analysis was at
y22 8C.
The protocol was approved by the Ethical Committee
of the Medical Faculty, University of Leuven, Belgium.
2.2. Quantification of EL-1
For each of 25 patients EL-1 was determined on each
sample in duplicate using the commercially available
sandwich ELISA-kit after an overnight extraction. Fecal
EL-1 was measured according to the manufacturer’s
guidelines (Schebo. Tech). ELISA plate wells are pre-
coated with a monoclonal antibody (clone IC 10A) to
human pancreatic EL-1. One hundred milligrams of
each stool sample was used in the assay. Diluted stool
samples were pipetted into the wells after extraction of
EL-1 with phosphate buffered saline extraction buffer,
each sample being assayed in duplicate. EL-1 in stool
sample and standards binds to the first antibody and is
immobilized. A biotin-conjugated second monoclonal
antibody (clone IID 5F) is added to each well. Finally,
a peroxidase–streptavidin solution is added and binds
the biotin-compound. The peroxidase oxidizes the sub-
strate solution (29-azino-bis-(3-ethylbenzothiazolin-6-
sulfonic acid) diammonium salt) with appearance of a
green color. Stop solution is added and the optical
density is read at 405 nm with a microtiter plate reader
(Biorad, Hercules, USA). Optical densities are trans-
formed to EL-1 concentrations from the standard curve
obtained with fixed EL-1 dilutions. A cut-off level of
200 mgyg was used, levels below 200 mgyg denoting
PI. Samples were measured after overnight extraction.
Intra-assay variability was calculated from duplicate
measurements.
2.3. Data analysis
Intra-assay and intra-patient variability were calculat-
ed as coefficients of variation (CV).
3. Results
3.1. Intra-assay variability
Mean intra-assay variability was 4.06% (range 1.22–
9.79%) based on duplicate measurements.
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Fig. 1. Fecal EL-1 results for PS patients and patients with PD. Fecal EL-1 results are represented. Means are indicated by horizontal bars.
Columns separated by dotted lines represent different patients. Full thickness vertical bar separates PS patients and patients with PD. The 200
mgygEL-1 cut-off level for diagnosis of PI is represented by the horizontal interrupted line. Percentages at the top of each column represent intra-
patient variabilities.
3.2. Intra-patient variability
All classical PI patients had EL-1 levels below detec-
tion limit. This finding was confirmed by the results of
the quality control lab. Thus, a CV could not be
calculated for these test results.
Individual test results for the classical PS and PD
patients are represented in Fig. 1.
For the classical PS patients we found a maximal CV
of 35% with EL-1 levels denoting PI in 1 patient. For
PD patients an equally high CV was found (maximal
CV 37%). For patient PD 1, 1 out of 7 samples had
EL-1 concentration consistent with PS. For patient PD
2, 3 out of 7 samples had EL-1 concentrations denoting
PI. These results were similar to the results found at the
quality control lab.
4. Discussion
In our CF patients with classical PI fecal EL-1 levels
were consistently below detection limit. Thus, a CV
could not be determined for this group. However, our
categorization based on symptoms of malabsorption and
on the result of the fecal fat excretion test entails that
our classical PI group comprises patients with severe
PI. The consistent EL-1 levels below 200 mgyg stool,
even below the detection limit, indicate that the EL-1
test can be safely used for diagnosing severe PI. This is
in accordance with the findings of Walkowiak et al.
who describe a 100% sensitivity for diagnosing severe
PI using the cut-off level of 200 mgEL-1yg stool w12x.
The intra-assay variability was (range 1.22–9.79%,
mean 4.06%) in agreement with findings by other
authors w7,10,11x.
However, we found important variability in fecal EL-
1 test results in CF patients with classical PS or PD,
confirming our experience in clinical practice. In clas-
sical PS patients the maximal CV found was 35%.
Patient PS 1 in whom the high CV was found had no
specific gastro-intestinal symptoms differentiating him
from the other PS patients. In the PD patients, the
maximal CV was 37%. Surprisingly, no data are avail-
able on intra-patient variability of EL-1 levels in CF
patients. Few data evaluate other populations. Phillips
et al. reported a mean intra-individual variation of 18%
for 20 triplicates in patients (mean age 57 years) being
investigated for occult fecal blood w11x. Terbrack exam-
ined the intra-patient variability in 10 consecutive day
stool samples from 10 PS non-CF children and found a
variability of 15% (range 3–28%) w8x. In a study by
Loser et al., a mean intra-patient variability of 15% was¨
reported (range 9–21%) on 10 consecutive day stool
samples of 8 adult patients suspected of having chronic
pancreatitis w6x.
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It is careful to state that interpretation of a single test
result (coming back as either PS or PI, relying on a cut-
off level) from a single random stool sample in patients
with PD may be hazardous because of the important
intra-patient variability in this group. The differences
reported in the PD are large enough to give rise to
misinterpretation of single test results. Both PD patients
were suffering from abdominal dyscomfort. On this
ground they were later on treated with enzyme supple-
ments, with good result. Unfortunately, we were unable
to include a large number of PS and PD patients, mainly
because they represent a small proportion of the CF
patient population.
We realize that the classification used (based on
clinical symptoms and fecal fat balance) is a rough one
and entails that the clinically PI group comprises mainly
severe PI subjects whereas the classical PS and PD
group might also contain patients with mild PI. However,
as duodenal intubation is hardly used in any center for
diagnosing PI in CF patients, we as others w7x rely on
the symptoms of malabsorption and the results of fecal
fat balances for diagnosing PI.
In conclusion, we described important variability in
EL-1 test results in CF patients. This is partly due to
the important intra-patient variability. We believe that
the EL-1 measurement is a reliable, sensitive and spe-
cific test for diagnosing PI in CF patients with overt
symptoms of malabsorption and an abnormal fat bal-
ance. However, in CF patients where the clinical picture
is less convincing, the fecal EL-1 test may not be the
simple, non-invasive test for diagnosing PI on a single
random stool sample.
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